Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade

Launched by UNIVERSITAS PADJADJARAN · Jan 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how quickly patients recover from the effects of a muscle relaxant called rocuronium after surgery. Specifically, it compares two reversal medications: sugammadex, which is known for providing a quicker recovery, and neostigmine, which tends to have a longer and less predictable recovery time. The goal is to find out if using half the usual dose of sugammadex can help patients recover faster than with neostigmine.

To be eligible for this trial, participants should be between 18 and 59 years old and must have undergone a specific type of surgery called laparoscopic cholecystectomy using rocuronium. Those who have certain health conditions, such as kidney problems or severe allergies to the study medications, will not be included. Participants in the trial will receive either sugammadex or neostigmine after their surgery and will be monitored to see how quickly they recover from the effects of the muscle relaxant. This research is important as it could help improve recovery times for patients after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who underwent laparoscopic cholecystectomy under general anesthesia
• • Using muscle relaxant rocuronium
• • Aged 18-59 years
• • American Society of Anesthesiologists (ASA) physical status classification of 1 or 2.
• Exclusion Criteria:
• • History of drug allergies to the agents used
• • Renal dysfunction
• • Musculoskeletal disorders
• • Central nervous system disorders
• • Difficult airways requiring intubation without the use of muscle relaxants.